Condition (MeSH)
Papilledema
ClinicalTrials.gov lists 28 trials for Papilledema or a narrower condition beneath it. National Eye Institute (NEI) has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
28 of the 28 trials are tagged with Papilledema itself; the rest are tagged with a narrower condition beneath it.
When did Papilledema trials start? (15)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 4
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2024 | 2 |
| 2023 | 3 |
| 2022 | 2 |
| 2021 | 3 |
| 2020 | 1 |
| 2019 | 1 |
| 2018 | 1 |
| 2017 | 2 |
| 2015 | 1 |
| 2014 | 2 |
Showing 10 of 15 earlier years.
No forecast is made for this condition: it averages 1.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Papilledema trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 6 |
| Phase 1/2 | 1 |
| Phase 2 | 1 |
| Phase 2/3 | 2 |
| Phase 4 | 3 |
| Not applicable | 5 |
| Observational | 10 |
How many Papilledema trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 2 |
| Completed | 12 |
| Terminated | 2 |
| Withdrawn | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Papilledema trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Eye Institute (NEI) | 2 |
| Boston Neurosciences | 1 |
| Fondation Ophtalmologique Adolphe de Rothschild | 1 |
| Institut National de la Santé Et de la Recherche Médicale, France | 1 |
| Kovach Eye Institute | 1 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Papilledema? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Nepafenac | 1 |
| AZD4017 | 1 |
| Semaglutide | 1 |
| Bromfenac | 1 |
| Prednisone | 1 |
Interventions as named in the registry (8)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| ranibizumab PRN | 2 |
| Anakinra alone (stages 2b/3) | 1 |
| Dexamethasone Intracanalicular Insert, 0.4 mg | 1 |
| Acetazolamide Pill | 1 |
| Dexamethasone/Dexamethasone acetate | 1 |
Showing 5 of 8 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Papilledema trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Headache | 5 | 1 |
| Live Birth | 2 | 1 |
| Lung infection | 2 | 1 |
| Meningitis | 2 | 1 |
| Pain | 2 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Papilledema? (76)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| The Vienna idiopathic intracranial hypertension database-An Austrian registry. | Wiener klinische Wochenschrift | 2024 | Yes |
| B-mode transorbital ultrasonography for the diagnosis of idiopathic intracranial hypertension: an updated systematic review and meta-analysis. | Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology | 2023 | Yes |
| An update on idiopathic intracranial hypertension in adults: a look at pathophysiology, diagnostic approach and management. | Journal of neurology | 2021 | Yes |
| Ophthalmic changes in a spaceflight analog are associated with brain functional reorganization. | Human brain mapping | 2021 | Yes |
| Role of tumor necrosis factor-alpha in the pathophysiology of idiopathic intracranial hypertension. | Acta neurologica Scandinavica | 2021 | Yes |
Showing 5 of 76 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.